biote director awarded options and RSUs

biote Corp. director Dana Lynn Jacoby received new equity awards.

Rhea-AI Filing Summary

biote Corp. director Dana Lynn Jacoby received new equity awards. She was granted stock options for 130,000 shares of Class A Common Stock at an exercise price of $2.20 per share, expiring on May 11, 2036. These options vest on the earlier of May 12, 2027 or the day prior to the company’s 2027 annual stockholders meeting, subject to continued service.

She also received 37,777 Deferred Settlement RSUs, each economically equivalent to one share of Class A Common Stock. These RSUs are fully vested upon grant, with settlement deferred until calendar year 2027 or her separation from service, whichever occurs first. Following these awards, she holds 130,000 options and 59,364 Deferred Settlement RSUs directly.

Insider Trade Summary

Grant/Award: 167,777 shares

Grant/Award 2 txns

Insider Jacoby Dana Lynn

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Settlement RSU	37,777	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	130,000	$0.00	$0.00

Holdings After Transaction: Deferred Settlement RSU — 59,364 contracts (Direct); Stock Option (Right to Buy) — 130,000 contracts (Direct)

Footnotes (3)

1. F1. Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock.
2. F2. The Deferred Settlement RSUs are fully vested upon grant, but settlement will be deferred until the earlier of calendar year 2027 or the date of the Reporting Person's separation from service.
3. F3. All shares subject to the option award shall vest on the earlier of May 12, 2027 or the day prior to the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Stock options granted: 130,000 options Option exercise price: $2.20 per share Option vesting date: May 12, 2027 +3 more

6 metrics

Stock options granted 130,000 options Exercise price $2.20, expire May 11, 2036

Option exercise price $2.20 per share Class A Common Stock underlying options

Option vesting date May 12, 2027 Or day before 2027 annual stockholders meeting

Deferred Settlement RSUs granted 37,777 RSUs Each equivalent to one share of Class A Common Stock

RSU settlement timing Calendar year 2027 Or on separation from service, whichever occurs first

RSUs held after grant 59,364 RSUs Total Deferred Settlement RSUs following transaction

Key Terms

Deferred Settlement RSU, economic equivalent, exercise price, vest, +1 more

5 terms

Deferred Settlement RSU financial

"The Deferred Settlement RSUs are fully vested upon grant, but settlement will be deferred..."

economic equivalent financial

"Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock."

exercise price financial

"conversion_or_exercise_price": "2.2000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"All shares subject to the option award shall vest on the earlier of May 12, 2027..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

separation from service financial

"settlement will be deferred until the earlier of calendar year 2027 or the date of the Reporting Person's separation from service."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did biote (BTMD) director Dana Lynn Jacoby receive?

Dana Lynn Jacoby received stock options on 130,000 shares at an exercise price of $2.20 and 37,777 Deferred Settlement RSUs. Each RSU is economically equivalent to one share of Class A Common Stock, providing additional equity-based compensation.

When do Dana Lynn Jacoby’s new biote (BTMD) stock options vest?

All 130,000 stock options vest on the earlier of May 12, 2027 or the day before biote’s 2027 annual stockholders meeting. Vesting is conditioned on her continuous service with the company through the applicable vesting date.

How are the biote (BTMD) Deferred Settlement RSUs structured for Dana Lynn Jacoby?

The 37,777 Deferred Settlement RSUs are fully vested at grant but settle later. Settlement occurs in calendar year 2027 or on the date of her separation from service, whichever comes first, aligning payout timing with future service or departure.

What does each Deferred Settlement RSU represent for biote (BTMD) director Dana Lynn Jacoby?

Each Deferred Settlement RSU is the economic equivalent of one share of biote’s Class A Common Stock. This means the RSUs mirror the value of actual shares, giving her equity-linked compensation without immediate share issuance.

What are Dana Lynn Jacoby’s holdings after these biote (BTMD) equity awards?

After the reported awards, she directly holds stock options on 130,000 shares and 59,364 Deferred Settlement RSUs. These positions reflect her derivative-based exposure to biote’s Class A Common Stock rather than immediate ownership of common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 06:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jacoby Dana Lynn

(Last) (First) (Middle)

C/O BIOTE CORP.

1875 W. WALNUT HILL LN #100

(Street)

IRVING TEXAS 75038

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
biote Corp. [ BTMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Settlement RSU	(1)	05/12/2026		A		37,777		(2)	(2)	Class A Common Stock	37,777	$0.00	59,364	D
Stock Option (Right to Buy)	$2.2	05/12/2026		A		130,000		(3)	05/11/2036	Class A Common Stock	130,000	$0.00	130,000	D

Explanation of Responses:

1. Each Deferred Settlement RSU is the economic equivalent of one share of Issuer Class A Common Stock.

2. The Deferred Settlement RSUs are fully vested upon grant, but settlement will be deferred until the earlier of calendar year 2027 or the date of the Reporting Person's separation from service.

3. All shares subject to the option award shall vest on the earlier of May 12, 2027 or the day prior to the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Kendal McNeely, as Attorney-in-Fact for Dana L. Jacoby	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)